COVID-19 Drug-Screening and Resistance Hub (CRUSH)

CRUSH成立于2020年，旨在解决抗病毒药物开发领域的严重空白。对COVID-19大流行的应对表明，在帮助开发针对高后果病毒的治疗方法和设备方面，需求很高，但设施和专业知识供应有限。CVR是英国为数不多的拥有必要基础设施和病毒学专业知识以支持此类研究的机构之一。我们已经开发了可以支持SARS-CoV-2研究的模型，但它们必须在高隔离设施（称为生物安全3级，BSL-3）中处理，并且需要专门的分子病毒学专业知识。这种类型的工作可以帮助筛选和确定潜在的抗病毒药物，最终可以用来帮助病人。CRUSH活动最初侧重于SARS-CoV-2，但我们现在对我们的模型进行了调整，以包括其他令人担忧的新出现病毒，例如猴痘。我们想让CRUSH成为一个马厩？和可持续吗?英国研究界的资源？为了加速药物的研发？已知的还是新奇的？高后果?病毒需要高防护设施。CRUSH及其合作伙伴的一项战略目标是为整个生命科学部门更广泛的合作和创新奠定基础，并为迅速应对未来的病毒爆发做好准备。

CRUSH was founded in 2020 to address an acute gap in the landscape of antiviral development. The response to the COVID-19 pandemic demonstrated the high demand and limited provision of facilities and expertise to aid the development of therapeutics and devices targeting high-consequence viruses. The CVR is one of a limited number of UK institutions with the necessary infrastructure and virology expertise to support such studies. We have developed models that can support SARS-CoV-2 research, but they must be handled in high containment facilities (known as biosafety level 3, BSL-3) and require specialised molecular virology expertise. This type of work can help screen and identify potential antiviral drugs that can ultimately be used to help patients. CRUSH activities have initially focused on SARS-CoV-2, but we have now adapted our models to include other emerging viruses of concern, e.g. monkeypox. We want CRUSH to be a stable?and sustainable?resource for the UK’s research communities?to accelerate drug discovery for?any?known or novel?high consequence?virus requiring high containment facilities. A strategic goal of CRUSH and partners is to establish a foundation for broader collaboration and innovation across the Life Sciences sector and to be prepared to rapidly respond to future viral outbreaks.